📊 UTHR Key Takeaways
Is UNITED THERAPEUTICS Corp (UTHR) a Good Investment?
UTHR demonstrates exceptional fundamental strength with 82.9% gross margins, 41.7% operating margins, and remarkable 46.4% free cash flow margin. The company combines solid 10.6% revenue growth with faster 13.1% EPS growth, indicating improving per-share economics, while maintaining a fortress balance sheet with zero debt and $1.3B cash, demonstrating financial resilience in a competitive pharma sector.
Why Buy UNITED THERAPEUTICS Corp Stock? UTHR Key Strengths
- Exceptional profitability margins across all levels (gross, operating, net) indicating strong pricing power and operational efficiency
- Robust free cash flow generation of $362.5M (46.4% margin) provides financial flexibility for R&D and shareholder returns
- Zero long-term debt with $1.3B cash and 4.79x current ratio, offering significant downside protection and strategic optionality
- EPS growth (13.1%) outpacing revenue growth (10.6%) indicates improving operational leverage and per-share value creation
- Strong balance sheet with $5.9B equity, minimizing financial risk
UTHR Stock Risks: UNITED THERAPEUTICS Corp Investment Risks
- Pharmaceutical sector exposure to patent expirations, regulatory changes, and drug development pipeline risks
- Relatively low ROE (4.7%) and ROA (4.1%) suggest capital may not be deployed at optimal returns despite margin excellence
- Significant insider activity (75 Form 4 filings in 90 days) warrants monitoring for potential selling pressure
- Moderate revenue growth rate of 10.6% YoY may face pressure from competitive dynamics or market saturation
Key Metrics to Watch
- Free cash flow sustainability and margin trajectory as revenue scales
- Revenue growth acceleration and product pipeline success rates
- Return on equity improvement trajectory and capital efficiency metrics
- Operating margin maintenance under pricing pressure or cost inflation scenarios
UNITED THERAPEUTICS Corp (UTHR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 46.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.79x current ratio provides a solid financial cushion.
UTHR Profit Margin, ROE & Profitability Analysis
UTHR vs Healthcare Sector: How UNITED THERAPEUTICS Corp Compares
How UNITED THERAPEUTICS Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is UNITED THERAPEUTICS Corp Stock Overvalued? UTHR Valuation Analysis 2026
Based on fundamental analysis, UNITED THERAPEUTICS Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
UNITED THERAPEUTICS Corp Balance Sheet: UTHR Debt, Cash & Liquidity
UTHR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: UNITED THERAPEUTICS Corp's revenue has grown significantly by 89% over the 5-year period, indicating strong business expansion. The most recent EPS of $19.81 reflects profitable operations.
UTHR Revenue Growth, EPS Growth & YoY Performance
UTHR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $781.5M | $274.9M | $5.82 |
| Q3 2025 | $748.9M | $309.1M | $6.39 |
| Q2 2025 | $714.9M | $278.1M | $5.85 |
| Q1 2025 | $677.7M | $306.6M | $6.17 |
| Q3 2024 | $609.4M | $267.6M | $5.38 |
| Q2 2024 | $596.5M | $259.2M | $5.24 |
| Q1 2024 | $506.9M | $240.9M | $4.86 |
| Q3 2023 | $516.0M | $239.3M | $4.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
UNITED THERAPEUTICS Corp Dividends, Buybacks & Capital Allocation
UTHR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for UNITED THERAPEUTICS Corp (CIK: 0001082554)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UTHR
What is the AI rating for UTHR?
UNITED THERAPEUTICS Corp (UTHR) has an AI rating of STRONG BUY with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UTHR's key strengths?
Claude: Exceptional profitability margins across all levels (gross, operating, net) indicating strong pricing power and operational efficiency. Robust free cash flow generation of $362.5M (46.4% margin) provides financial flexibility for R&D and shareholder returns.
What are the risks of investing in UTHR?
Claude: Pharmaceutical sector exposure to patent expirations, regulatory changes, and drug development pipeline risks. Relatively low ROE (4.7%) and ROA (4.1%) suggest capital may not be deployed at optimal returns despite margin excellence.
What is UTHR's revenue and growth?
UNITED THERAPEUTICS Corp reported revenue of $781.5M.
Does UTHR pay dividends?
UNITED THERAPEUTICS Corp does not currently pay dividends.
Where can I find UTHR SEC filings?
Official SEC filings for UNITED THERAPEUTICS Corp (CIK: 0001082554) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UTHR's EPS?
UNITED THERAPEUTICS Corp has a diluted EPS of $5.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is UTHR a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, UNITED THERAPEUTICS Corp has a STRONG BUY rating with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is UTHR stock overvalued or undervalued?
Valuation metrics for UTHR: ROE of 4.7% (sector avg: 15%), net margin of 35.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy UTHR stock in 2026?
Our dual AI analysis gives UNITED THERAPEUTICS Corp a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is UTHR's free cash flow?
UNITED THERAPEUTICS Corp's operating cash flow is $463.3M, with capital expenditures of $100.8M. FCF margin is 46.4%.
How does UTHR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 35.2% (avg: 12%), ROE 4.7% (avg: 15%), current ratio 4.79 (avg: 2).